401 in final stage of trials27 Oct 2019 12:06
Dr Suzy Dilly, CEO of ValiSeek, commented: "The external validation from both the Advisory Board and wider industry, has provided increased confidence that VAL401, the product, has a valued and needed place in the market. These developments are a valuable addition to our licensing package, clarifying the final stages of clinical testing towards commercial use."